cas 140-69-2|| where to buy (4-Methoxybenzyl)hydrazine

Nombre del producto:(4-Methoxybenzyl)hydrazine

IUPAC Name:[(4-methoxyphenyl)methyl]hydrazine

Unidad de embalaje	Stock disponible	Precio($)
CM195480-5g	in stock	șŭň
CM195480-10g	in stock	ƻșǺ
CM195480-25g	in stock	Əŭƅ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 140-69-2 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :140-69-2; Fórmula molecular:C8H12N2O; Punto de fusión:-; Código de sonrisas:NNCC1=CC=C(OC)C=C1; Densidad:

: Número de catálogo:CM195480; Peso molecular:152.2; Punto de ebullición:; Nº Mdl:MFCD07786530; Almacenamiento:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Quemliclustat; Data from a phase 1b study of Quemliclustat-based regimens showed promising overall survival in treatment-naïve metastatic pancreatic cancer. Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone.
Quemliclustat is an investigational, potent and selective small molecule CD73 inhibitor. CD73 is the primary enzymatic producer of immunosuppressive adenosine in the tumor microenvironment, and high CD73 expression is associated with significantly poorer prognosis in several tumor types. Quemliclustat has been shown to block the production of adenosine. Once the immunosuppressive effects of adenosine are removed, activation of antitumor immune cells may be restored, resulting in cancer cell death.